Scholar Rock Holding (FRA:2QK) FCF Yield %: -4.61 (As of Jul. 01, 2026)


FRA:2QK Scholar Rock Holding Corp FRA:2QK
26 GF Score
Price €48.00
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding FCF Yield %?

Scholar Rock Holding FRA:2QK +0.08% 26 FCF Yield % is -4.61 as of Jul. 01, 2026. GuruFocus rates FRA:2QK with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, Scholar Rock Holding ranks better than 63.39% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Scholar Rock Holding's Trailing 12-Month Free Cash Flow is €-261.27 Mil, and Market Cap is €5,787.28 Mil. Therefore, Scholar Rock Holding's FCF Yield % for today is -4.61%.

The historical rank and industry rank for Scholar Rock Holding's FCF Yield % or its related term are showing as below:

FRA:2QK' s FCF Yield % Range Over the Past 10 Years
Min: -79.33   Med: -9.76   Max: 4.66
Current: -4.61


During the past 10 years, the highest FCF Yield % of Scholar Rock Holding was 4.66%. The lowest was -79.33%. And the median was -9.76%.

FRA:2QK's FCF Yield % is ranked better than
63.39% of 1415 companies
in the Biotechnology industry
Industry Median: -9.49 vs FRA:2QK: -4.61

Scholar Rock Holding's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Scholar Rock Holding FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Scholar Rock Holding FCF Yield % Related Terms


Scholar Rock Holding FCF Yield % Historical Data

* Premium members only.

The historical data trend for Scholar Rock Holding's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scholar Rock Holding FCF Yield % Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.95 -32.80 -9.58 -4.85 -6.23

Scholar Rock Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.26 -9.17 -7.32 -6.26 -6.35

FRA:2QK vs COGT, CGON, PTCT: FCF Yield % Comparison

For the Biotechnology subindustry, Scholar Rock Holding's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scholar Rock Holding FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's FCF Yield % falls into.


FRA:2QK
26GF Score
Scholar Rock Holding Corp FRA:2QK
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Scholar Rock Holding's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-256.744 / 4121.518
=-6.23%

Scholar Rock Holding's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-71.076 * 4 / 4478.3104
=-6.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -4.61 mean?
Scholar Rock Holding (FRA:2QK) has a FCF Yield % of -4.61 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #518 out of 1415 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Scholar Rock Holding's FCF Yield % too high?
Scholar Rock Holding's current FCF Yield % is -4.61. Based on the distribution chart, Scholar Rock Holding ranks #518 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scholar Rock Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's FCF Yield % compare to COGT and CGON?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #518 out of 1415 companies for FCF Yield %. This puts Scholar Rock Holding in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current FCF Yield % is -4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current FCF Yield % of -4.61. The current FCF Yield % is -4.61. Scholar Rock Holding's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current FCF Yield % is -4.61 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
26GF Score

Get the complete analysis for FRA:2QK

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.00
Price